Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1991 Apr;31(4):439–443. doi: 10.1111/j.1365-2125.1991.tb05560.x

Acute reduction of TxA2 platelet binding sites after in vivo administration of a TxA2 receptor inhibitor.

P A Modesti 1, A Colella 1, I Cecioni 1, G F Gensini 1, R Abbate 1, G G Neri Serneri 1
PMCID: PMC1368332  PMID: 1828683

Abstract

1. Picotamide has been shown to interfere competitively with the thromboxane A2 (TxA2) platelet receptor. In the present study the effect of in vivo administration of picotamide on TxA2 human platelet receptors was investigated in 10 healthy subjects. 2. Picotamide (300 mg x 3 daily) or placebo were administered in a double-blind, cross-over, placebo controlled study, each treatment lasting 1 week with a 2 week interval period. TxA2 receptors were investigated by a direct radioligand binding assay method employing [125I]-PTA-OH as labelled ligand. Platelet studies were performed on the first day of treatment immediately before and 2, 4 and 8 h after the ingestion of the drug. The effects of chronic administration were assessed on the seventh day. 3. Two and 4 h after the administration of picotamide 300 mg orally platelet TxA2 receptors were significantly reduced from 1366 +/- 237 to 957 +/- 221 (P less than 0.05) and 753 +/- 119 receptors/platelet (mean +/- s.d.) (P less than 0.03). After 8 h platelet receptor population was restored (1362 +/- 324, NS). The same pattern was observed after 7 days of treatment. Thus picotamide seems to induce a short lasting down regulation of platelet TxA2 receptors.

Full text

PDF
441

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alt U., Leigh P. J., Wilkins A. J., Morris P. K., MacDermot J. Desensitization of iloprost responsiveness in human platelets follows prolonged exposure to iloprost in vitro. Br J Clin Pharmacol. 1986 Jul;22(1):118–119. [PMC free article] [PubMed] [Google Scholar]
  2. Benovic J. L., Pike L. J., Cerione R. A., Staniszewski C., Yoshimasa T., Codina J., Caron M. G., Lefkowitz R. J. Phosphorylation of the mammalian beta-adrenergic receptor by cyclic AMP-dependent protein kinase. Regulation of the rate of receptor phosphorylation and dephosphorylation by agonist occupancy and effects on coupling of the receptor to the stimulatory guanine nucleotide regulatory protein. J Biol Chem. 1985 Jun 10;260(11):7094–7101. [PubMed] [Google Scholar]
  3. Cheng Y., Prusoff W. H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol. 1973 Dec 1;22(23):3099–3108. doi: 10.1016/0006-2952(73)90196-2. [DOI] [PubMed] [Google Scholar]
  4. Crouch M. F., Lapetina E. G. Dual mechanisms of platelet hormone receptor desensitization. Differential importance between agonists of protein kinase C-dependent and -independent pathways. J Biol Chem. 1989 Jan 5;264(1):584–588. [PubMed] [Google Scholar]
  5. Edwards R. J., MacDermot J., Wilkins A. J. Prostacyclin analogues reduce ADP-ribosylation of the alpha-subunit of the regulatory Gs-protein and diminish adenosine (A2) responsiveness of platelets. Br J Pharmacol. 1987 Mar;90(3):501–510. doi: 10.1111/j.1476-5381.1987.tb11199.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Harden T. K. Agonist-induced desensitization of the beta-adrenergic receptor-linked adenylate cyclase. Pharmacol Rev. 1983 Mar;35(1):5–32. [PubMed] [Google Scholar]
  7. Jaschonek K., Faul C., Schmidt H., Renn W. Desensitization of platelets to iloprost. Loss of specific binding sites and heterologous desensitization of adenylate cyclase. Eur J Pharmacol. 1988 Mar 1;147(2):187–196. doi: 10.1016/0014-2999(88)90777-7. [DOI] [PubMed] [Google Scholar]
  8. Liel N., Mais D. E., Halushka P. V. Desensitization of platelet thromboxane A2/prostaglandin H2 receptors by the mimetic U46619. J Pharmacol Exp Ther. 1988 Dec;247(3):1133–1138. [PubMed] [Google Scholar]
  9. Modesti P. A., Abbate R., Gensini G. F., Colella A., Serneri G. G. Kinetic analysis of a TxA2 receptor antagonist. Evidence for the existence of an uptake system. Eicosanoids. 1990;3(3):139–143. [PubMed] [Google Scholar]
  10. Modesti P. A., Colella A., Abbate R., Gensini G., Neri Serneri G. Competitive inhibition of platelet thromboxane A2 receptor binding by picotamide. Eur J Pharmacol. 1989 Oct 4;169(1):85–93. doi: 10.1016/0014-2999(89)90820-0. [DOI] [PubMed] [Google Scholar]
  11. Modesti P. A., Fortini A., Abbate R., Gensini G. F. Age related changes of platelet prostacyclin receptors in humans. Eur J Clin Invest. 1985 Aug;15(4):204–208. doi: 10.1111/j.1365-2362.1985.tb00169.x. [DOI] [PubMed] [Google Scholar]
  12. Modesti P. A., Fortini A., Poggesi L., Boddi M., Abbate R., Gensini G. F. Acute reversible reduction of PGI2 platelet receptors after iloprost infusion in man. Thromb Res. 1987 Dec 15;48(6):663–669. doi: 10.1016/0049-3848(87)90432-4. [DOI] [PubMed] [Google Scholar]
  13. Murray R., FitzGerald G. A. Regulation of thromboxane receptor activation in human platelets. Proc Natl Acad Sci U S A. 1989 Jan;86(1):124–128. doi: 10.1073/pnas.86.1.124. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Narumiya S., Okuma M., Ushikubi F. Binding of a radioiodinated 13-azapinane thromboxane antagonist to platelets: correlation with antiaggregatory activity in different species. Br J Pharmacol. 1986 Jun;88(2):323–331. doi: 10.1111/j.1476-5381.1986.tb10208.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Neri Serneri G. G., Modesti P. A., Fortini A., Abbate R., Lombardi A., Gensini G. F. Reduction in prostacyclin platelet receptors in active spontaneous angina. Lancet. 1984 Oct 13;2(8407):838–841. doi: 10.1016/s0140-6736(84)90874-2. [DOI] [PubMed] [Google Scholar]
  16. Sato T., Hashizume T., Nakao K., Akiba S., Fujii T. Platelet desensitization by arachidonic acid is associated with the suppression of endoperoxide/thromboxane A2 binding to the membrane receptor. Biochim Biophys Acta. 1989 Aug 18;992(2):168–173. doi: 10.1016/0304-4165(89)90006-8. [DOI] [PubMed] [Google Scholar]
  17. Sinzinger H., Silberbauer K., Horsch A. K., Gall A. Decreased sensitivity of human platelets to PGI2 during long-term intraarterial prostacyclin infusion in patients with peripheral vascular disease--a rebound phenomenon? Prostaglandins. 1981 Jan;21(1):49–51. doi: 10.1016/0090-6980(81)90195-7. [DOI] [PubMed] [Google Scholar]
  18. Weiland G. A., Molinoff P. B. Quantitative analysis of drug-receptor interactions: I. Determination of kinetic and equilibrium properties. Life Sci. 1981 Jul 27;29(4):313–330. doi: 10.1016/0024-3205(81)90324-6. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES